Search

Displaying results 8851 - 8860 of 10000 in total
  1. Drug

    Peptide YY (3-36)

    go.drugbank.com/drugs/DB05004
    Investigational

    Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.

    Synonyms: PYY 3-36, PYY(3-36)
  2. Drug

    Taberminogene vadenovec

    go.drugbank.com/drugs/DB05011
    Experimental

    Taberminogene vadenovec (EG004) is a novel product consisting of a local delivery device and a gene-based medicine, being developed to prevent the blocking of veins and arteries that frequently occurs … that their blood can be regularly filtered using a dialysis machine.

  3. Drug

    Amonafide

    go.drugbank.com/drugs/DB05022
    Investigational

    Amonafide is a substance that is being studied in the treatment of cancer. It belongs to the families of drugs called topoisomerase inhibitors and intercalating agents.

    Salts: Amonafide L-malateCategories: Compounds used in a research, industrial, or household setting, Heterocyclic Compounds, 2-Ring
  4. Drug

    ATL1101

    go.drugbank.com/drugs/DB05023
    Experimental

    ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis. … ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis.

  5. Drug

    Lancovutide

    go.drugbank.com/drugs/DB05029
    Investigational

    Lancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis. … Lantibiotics are bacteriocins that are characterized by the presence of a high proportion of unusual amino acids.

  6. Drug

    Ularitide

    go.drugbank.com/drugs/DB05034
    Investigational

    Ularitide is a synthetic form of urodilatin, a naturally occurring human natriuretic peptide that is involved in regulating blood pressure and the excretion of water and sodium from the kidneys. … Ularitide is currently in Phase 2 development as a potential treatment for patients with acute decompensated heart failure (ADHF).

  7. Drug

    Eprotirome

    go.drugbank.com/drugs/DB05035
    Investigational

    Eprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia.

  8. Drug

    SGS518

    go.drugbank.com/drugs/DB05042
    Experimental

    SGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).

  9. Drug

    Milveterol

    go.drugbank.com/drugs/DB05043
    Investigational

    GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.

  10. Drug

    Cannabinor

    go.drugbank.com/drugs/DB05048
    Experimental

    Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.